| Identification | Back Directory | [Name]
1-(BETA-D-Xylofuranosyl)-5-methylcytosine | [CAS]
18492-10-9 | [Synonyms]
5-Methyl-xylo-cytidine
1-(b-D-Xylofuranosyl)-5-methylcytosine
1-(BETA-D-Xylofuranosyl)-5-methylcytosine
2(1H)-Pyrimidinone, 4-amino-5-methyl-1-β-D-xylofuranosyl- | [Molecular Formula]
C10H15N3O5 | [MDL Number]
MFCD32215215 | [MOL File]
18492-10-9.mol | [Molecular Weight]
257.243 |
| Chemical Properties | Back Directory | [Melting point ]
205-207 °C(Solv: ethanol (64-17-5)) | [Boiling point ]
537.5±60.0 °C(Predicted) | [density ]
1.79±0.1 g/cm3(Predicted) | [pka]
13.48±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
1-(β-D-Xylofuranosyl)-5-methylcytosine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005
[2] Gowher H, et al. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther. 2004 Nov;3(11):1062-8. DOI:10.4161/cbt.3.11.1308 |
|
|